Copyright © Inderes 2011 - present. All rights reserved.
  • Uusimmat
  • Pörssi
    • Aamukatsaus
    • Osakevertailu
    • Pörssikalenteri
    • Osinkokalenteri
    • Analyysi
    • Artikkelit
    • Sisäpiirin kaupat
  • inderesTV
  • Mallisalkku
  • Foorumi
  • Premium
  • Femme
  • Nora AI
  • Opi
    • Sijoituskoulu
    • Q&A
    • Analyysikoulu
  • Meistä
    • Seurantayhtiöt
    • Tiimi
Lehdistötiedote

Prolight Diagnostics achieves assay design freeze for Psyros™ point-of-care cartridge – A key milestone toward commercialisation

Prolight Diagnostics

Prolight Diagnostics today announced it has reached assay design freeze for its Psyros™ point-of-care cartridge, marking a major development milestone for the Psyros platform and an important step toward commercialisation.

The design freeze confirms the final assay configuration and performance characteristics, freezing the cartridge chemistry. With this milestone achieved, Prolight can now transition to the final optimization of its manufacturing process, focusing on scalability, consistency, and production efficiency ahead of the upcoming clinical performance study.

“This achievement reflects the strong progress our team has made in turning the Psyros vision into a robust, manufacturable product,” said Aileen McGettrick, CSO of Prolight Diagnostics. “With assay design freeze complete, we can now concentrate on refining manufacturing processes to support large-scale production and, ultimately, broad deployment in point-of-care settings.”

The Psyros platform is designed to deliver rapid, high-quality diagnostic analysis at the point of care, enabling timely clinical decision-making and improved patient pathways. Prolight will provide further updates as it advances through manufacturing optimization and progresses towards the clinical performance study.

For further information, please contact:
Ulf Bladin, CEO
E-mail: info@prolightdx.com
Phone: +46 73 582 39 87
Company website: www.prolightdx.com

About Us
Prolight Diagnostics AB develops innovative Point-of-Care systems. These are small, portable instruments and disposable cartridges for performing in-vitro diagnostic (IVD) tests from a drop of blood. We want to offer the foremost POC systems on the market for quick, reliable diagnosis of acute events. Our launch product will be for the measurement of high sensitive troponin, to aid in the rule-in and rule-out of myocardial infarction.
 
The company’s share is traded on the NGM Nordic SME marketplace, under the ticker PRLD.

Attachments
Prolight Diagnostics achieves assay design freeze for Psyros™ point-of-care cartridge – A key milestone toward commercialisation

Sosiaalinen media
  • Inderes Foorumi
  • Youtube
  • Facebook
  • Instagram
  • X (Twitter)
  • Tiktok
  • Linkedin
Yhteystiedot
  • info@inderes.fi
  • +358 10 219 4690
  • Porkkalankatu 5
    00180 Helsinki
Inderes
  • Meistä
  • Tiimi
  • Avoimet työpaikat
  • Inderes sijoituskohteena
  • Palvelut pörssiyhtiöille
Sivusto
  • UKK
  • Käyttöehdot
  • Tietosuojaseloste
  • Vastuuvapauslauseke
Inderesin vastuuvapauslauseke löytyy täältä. Kunkin Inderesin aktiivisessa seurannassa olevan osakkeen tarkemmat tiedot löytyvät kunkin osakkeen omilta yhtiösivuilta Inderes-sivustolla. © Inderes Oyj. Kaikki oikeudet pidätetään.